2026 NPPES data Hematology & Oncology Physician NPI 1598752842 M.D.
Verify on CMS →

PAUL KAYWIN, M.D.

Hematology & Oncology Physician in MIAMI, Florida. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
472
Medicare Part D claims · 114 beneficiaries · Hematology & Oncology Physician avg: 847
Generic prescribing
72%
generic claims · 28% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
64.7935/100
▼ 18 pts below national avg 83.1 · [object Object]
Industry payments
$2.8K
21 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

PAUL KAYWIN, M.D. reported a CMS MIPS final score of 64.7935/100 — below the 83.1 national average — and filed 472 Medicare Part D claims in 2023.

64.7935/100
MIPS score · -18 vs avg
472
Part D claims, 2023
72%
generic prescribing
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

PAUL KAYWIN, M.D.'s MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

65 6th percentile higher than 6% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). This entry sits in this band. 70–80: 118,074 scored providers (25%). Above this entry. 80–90: 129,887 scored providers (27%). Above this entry. 90–100: 189,403 scored providers (40%). Above this entry. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

PAUL KAYWIN, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about PAUL KAYWIN, M.D.?

Below national average

NPI registry status

Active

Issued 10/03/2005

NPI 1598752842

Primary specialty

Hematology & Oncology Physician

Mid-sized

11,215 US NPIs in this specialty

Medicare Part D claims

472 44% vs specialty avg

2023 prescription claims

Specialty avg: 847

MIPS final score

64.7935/100 18.3065% pts

Mid-tier band

vs 83.1 national avg

Specialty distribution in Florida

How Hematology & Oncology Physician compares to other specialties among Florida providers

Florida providers

Hematology & Oncology Physician share within Florida

1. Hematology & Oncology Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Hematology & Oncology Physician share within Florida

Medicare quality performance — MIPS

PAUL KAYWIN, M.D.'s 2023 MIPS final score plotted against the Hematology & Oncology Physician national average

Below national average
MIPS Final Score
64.7935/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Hematology & Oncology Physician) — 64.7935/100 vs national avg 83.1

0%100%National avg83%64.8%
MIPS final score (Hematology & Oncology Physician) — 64.7935/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

PAUL KAYWIN, M.D. appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding M.D. credentials at 8900 N KENDALL DR, MIAMI, FL, 33176, with a listed phone of (786) 596-2000. NPI 1598752842 was issued on 10/03/2005. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what KAYWIN most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 472 prescription claims written by this provider, covering 114 Medicare beneficiaries and totaling roughly $979K in drug spend, split 28% brand-name and 72% generic by claim count, with an opioid prescribing rate of 2.3%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 64.7935/100 for the 2023 performance year (Quality 61.7249, Cost 45.293), compared with the national average of 83.1.

Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,215 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

8900 N KENDALL DR
MIAMI, FL 33176

Provider Details

NPI 1598752842
Specialty Hematology & Oncology Physician
Credentials M.D.
Gender Male
NPI Issued 10/03/2005

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

64.7935
Final Score
Avg: 83.1
61.7249
Quality
45.293
Cost
99
Promoting Interoperability

Reporting: Group practice

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for PAUL KAYWIN, M.D.. Source: openpaymentsdata.cms.gov.

Total received

$2.8K

Largest payer

Boehringer Ingelheim Pharmaceuticals, Inc.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — Florida FLDOH 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~75K Florida medical licensees in 2023 — they are NOT specific to PAUL KAYWIN, M.D.. To verify PAUL KAYWIN, M.D.'s current license status, search the FLDOH public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

480
Total board actions, Florida 2023
Across 467 cases
6.40
Actions per 1,000 licensees
Florida statewide rate
monetary fine
Most common action type
138 cases

FLDOH publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Florida disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Above average

PAUL KAYWIN, M.D. — brand share 28.0%
Specialty average (est.)

28% brand-name claims vs 72% generic, on 472 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

472
Total Claims
$979K
Total Drug Cost
114
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
641
Total Day Supply
15,844
Brand vs Generic
28% brand / 72% generic
Brand Drug Cost
$969K
Generic Drug Cost
$10K
Opioid Claims
11 (2.3% rate)
Antibiotic Claims
12

Patient Demographics

Average Patient Age
74.0 years
Avg HCC Risk Score
2.66
Gender Split
60% female / 40% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What PAUL KAYWIN, M.D. prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Dexamethasone
62
Folic Acid
51
Gilotrif
Afatinib Dimaleate
36
Prochlorperazine Maleate
36
Eliquis
Apixaban
31
Ondansetron Hcl
26
Tagrisso
Osimertinib Mesylate
17
Hydroxyurea
14
Xarelto
Rivaroxaban
14
Prednisone
13

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Hematology & Oncology Physician Overview

How PAUL KAYWIN, M.D. fits within the Hematology & Oncology Physician landscape nationally.

11,215
Hematology & Oncology Physician Providers in US
54
States with Hematology & Oncology Physician
847
Avg Claims per Provider

PAUL KAYWIN, M.D.'s 472 claims are below the specialty average of 847.

Nearby Hematology & Oncology Physician Providers in Florida

Other clinicians with the same primary specialty enrolled in Florida, drawn from the same CMS NPPES roster as KAYWIN.

Compare Hematology & Oncology Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is PAUL KAYWIN, M.D.'s specialty?
PAUL KAYWIN, M.D. specializes in Hematology & Oncology Physician and practices in MIAMI, Florida. Credentials: M.D..
How much does PAUL KAYWIN, M.D. prescribe under Medicare Part D?
In 2023, PAUL KAYWIN, M.D. wrote 472 Medicare Part D claims totaling $979K in drug costs for 114 beneficiaries.
What is PAUL KAYWIN, M.D.'s Medicare quality score?
PAUL KAYWIN, M.D. has a CMS MIPS Final Score of 64.7935/100 (Quality: 61.7249, Cost: 45.293). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is PAUL KAYWIN, M.D. located?
PAUL KAYWIN, M.D. is located at 8900 N KENDALL DR, MIAMI, FL, 33176. Phone: (786) 596-2000.
What is PAUL KAYWIN, M.D.'s NPI number?
PAUL KAYWIN, M.D.'s National Provider Identifier (NPI) is 1598752842, issued on 10/03/2005.
Does PAUL KAYWIN, M.D. prescribe more brand-name or generic drugs?
PAUL KAYWIN, M.D.'s prescribing is 28% brand-name and 72% generic drugs by claim count, with $969K in brand drug costs.
Does PAUL KAYWIN, M.D. prescribe opioids?
Yes, PAUL KAYWIN, M.D. had 11 opioid claims in 2023 with an opioid prescribing rate of 2.3%.
How many Hematology & Oncology Physician providers are there in the US?
There are 11,215 Hematology & Oncology Physician providers across 54 states in the US. The average Hematology & Oncology Physician provider writes 847 Medicare Part D claims per year.
What drugs does PAUL KAYWIN, M.D. prescribe most often?
Based on 2023 Medicare Part D data, PAUL KAYWIN, M.D.'s most frequently prescribed drugs include Dexamethasone, Folic Acid, Gilotrif. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does PAUL KAYWIN, M.D. accept Medicare?
PAUL KAYWIN, M.D. appears in CMS Medicare data with 472 Part D claims and 114 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify PAUL KAYWIN, M.D.'s credentials?
PAUL KAYWIN, M.D.'s NPI is 1598752842 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology